Ditchcarbon
  • Contact
  1. Organizations
  2. Sinclair Pharma Limited
Public Profile
Pharmaceutical Preparation Manufacturing
GB
updated 23 days ago

Sinclair Pharma Limited Sustainability Profile

Company website

Sinclair Pharma Limited, a prominent player in the global aesthetics and dermatology industry, is headquartered in Great Britain. Founded in 1971, the company has established itself as a leader in innovative medical solutions, focusing on advanced products for skin health and aesthetic enhancement. With a strong presence in Europe, Asia, and the Americas, Sinclair Pharma is renowned for its unique offerings, including injectable fillers and skin rejuvenation treatments. The company’s commitment to research and development has led to significant milestones, positioning it as a trusted name in the market. Sinclair Pharma's core products, such as the well-regarded Ellansé and Silhouette Soft, are distinguished by their long-lasting results and biocompatibility. With a reputation for quality and innovation, Sinclair Pharma continues to make strides in the aesthetic sector, contributing to the evolving landscape of cosmetic medicine.

DitchCarbon Score

How does Sinclair Pharma Limited's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.

30

Industry Average

Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.

30

Industry Benchmark

Sinclair Pharma Limited's score of 30 is higher than 51% of the industry. This can give you a sense of how well the company is doing compared to its peers.

51%

Let us know if this data was useful to you

Sinclair Pharma Limited's reported carbon emissions

Inherited from Huadong Medicine Co., Ltd

Sinclair Pharma Limited, headquartered in Great Britain, currently does not report specific carbon emissions data, as indicated by the absence of emissions figures. The company is a current subsidiary of Huadong Medicine Co., Ltd, which may influence its climate-related initiatives and reporting practices. Despite the lack of direct emissions data, Sinclair Pharma Limited's climate commitments and reduction initiatives are not explicitly outlined. The company does not appear to have set specific reduction targets or participate in initiatives such as the Science Based Targets initiative (SBTi) or the Carbon Disclosure Project (CDP) at this time. As a subsidiary, Sinclair Pharma Limited may align its sustainability efforts with those of its parent company, Huadong Medicine Co., Ltd, which could include broader industry practices and commitments to reducing carbon footprints. However, without specific data or targets, the company's individual climate strategy remains unclear. In summary, while Sinclair Pharma Limited is part of a larger corporate structure that may have climate commitments, it currently lacks publicly available emissions data and defined reduction targets.

Unlock detailed emissions data

Access structured emissions data, company-specific emission factors, and source documents

20222023
Scope 1
11,305,600
00,000,000
Scope 2
-
-
Scope 3
-
-

How Carbon Intensive is Sinclair Pharma Limited's Industry?

Very low
Low
Medium
High
Very high
Some industries are more carbon intensive than others. Sinclair Pharma Limited's primary industry is Pharmaceutical Preparation Manufacturing, which is very low in terms of carbon intensity compared to other industries.

How Carbon Intensive is Sinclair Pharma Limited's Location?

Very low
Low
Medium
High
Very high
The carbon intensity of the energy grid powering a company's primary operations has a strong influence on its overall carbon footprint. This request for Sinclair Pharma Limited is in GB, which has a very low grid carbon intensity relative to other regions.

Sinclair Pharma Limited's Climate Goals (2030 & 2050)

Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.

Sinclair Pharma Limited has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.

Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact
RE 100
Climate Action 100
Race To Net Zero
Reduction Actions

Compare Sinclair Pharma Limited's Emissions with Industry Peers

IRIDEX Corporation

US
•
Medical, precision and optical instruments, watches and clocks (33)
Updated 2 months ago

InMode Ltd.

IL
•
Medical, precision and optical instruments, watches and clocks (33)
Updated about 1 month ago

Merz Pharma GmbH & Co. KGaA

DE
•
Pharmaceutical Preparation Manufacturing
Updated 11 days ago

Evolus, Inc.

US
•
Pharmaceutical Preparation Manufacturing
Updated about 1 month ago

Galderma S.A.

CH
•
Pharmaceutical Preparation Manufacturing
Updated 11 days ago

Revance Therapeutics, Inc.

US
•
Pharmaceutical Preparation Manufacturing
Updated 2 days ago

Let us know if this data was useful to you

Where does DitchCarbon data come from?

Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers

Ditchcarbon
v251030.3
[email protected]+44 203 475 7875Ditch Carbon Ltd167-169 Great Portland StreetLondon W1W 5PF
UL Solutions verification badge
CDP logo
Gartner Cool Vendor 2025 badge
ProductPortalScope 3 Tool FunctionalityDataIntegrationsPricing
CustomersHaleonGrant ThorntonHikmaRead all stories
SolutionsProcurement teamsSustainability teamsPlatform ownersCarbon accountants
ResourcesCalculation MethodologyDocumentationBlogFAQOrganizationsIndustriesSBTI APITrust CentreChangelog
AboutTeamCareersLicense AgreementPrivacy